The UT Health San Antonio pilot trial (NCT04785300) evaluated D+Q (dasatinib 100 mg + quercetin 1,000 mg × 2 days, biweekly for 12 weeks) in 15 early Alzheimer's disease patients. Preliminary findings include reduction in CSF SASP factors, reduction in p-tau-181 (a validated Alzheimer's biomarker), and a trend toward reduced amyloid-beta 1-42:1-40 ratio — all consistent with a senolytic effect on brain-resident senescent cells.

Can D+Q slow Alzheimer's progression?

The pilot data is promising but not conclusive. CSF biomarker improvements suggest biological activity. Whether this translates to slowed clinical progression will be answered by the ALSENLITE Phase 2 trial.

Is fisetin a better choice than D+Q for Alzheimer's prevention?

For prevention in healthy individuals, fisetin is more accessible, safer for self-directed use, and has documented CNS penetration. D+Q has more direct Alzheimer's clinical data but requires physician oversight and carries greater side effect risk.